Navigation Links
Radioactive Seed Therapy Shows Significant Reduction in Lung Cancer Recurrence
Date:9/23/2008

Study Shows near 80% Improvement In Outcomes

PITTSBURGH, Sept. 23 /PRNewswire/ -- Radiation oncologists at Allegheny General Hospital (AGH) in Pittsburgh today will report to the American Society for Therapeutic Radiology and Oncology (ASTRO) in Boston that a newer, minimally invasive approach to treating high risk patients with Stage I non-small cell lung carcinoma (NSCLC) may significantly reduce the risk of local disease recurrence.

Developed at AGH over the past decade, the procedure involves removing only the cancerous section of the lung and enveloping the surgical site in a mesh material that is embedded with radioactive seeds. The seeds emit a low dose of radiation over a prolonged period of time in an effort to eradicate any remaining cancer cells.

Lung cancer is the leading cause of cancer death in the United States. Non-small cell lung carcinoma is the most common form of the disease, accounting for an estimated 85% of all cases. Stage I NSCLC is characterized by disease that is localized in the lung with no metastasis to the lymph node system.

"The standard of care for patients with this particular disease is a lobectomy, or surgical removal of the entire lobe of the lung. Many patients, however, are considered high risk for this procedure due to cardiopulmonary complications or other co-morbidities. In these cases, sublobar wedge resection is a more tolerable approach, but one that carries a much higher chance of local cancer recurrence," said Athanasios Colonias, MD, an AGH radiation oncologist and the study's principal investigator.

"Our study suggests that when intraoperative 125I Vicryl(R) mesh brachytherapy is added to sublobar resection, the local treatment failure rate is substantially reduced," Dr. Colonias said.

Dr. Colonias and his AGH colleagues examined the outcomes of 145 high-risk patients with Stage I NSCLC who underwent sublobar resection (SLR) with adjuvant intraoperative mesh
'/>"/>

SOURCE Allegheny General Hospital
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting
2. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
3. Breast MRI Scan Could Determine Need for Radiation Therapy
4. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
5. AMT Obtains License to Amgens GDNF Gene to Develop Treatment for Parkinsons Disease with AMTs Proprietary Gene Therapy Platform
6. Keraderm to Release $100 Phototherapy Treatment for Fungal Nail Infections
7. St. Jude Study Finds Treatment With New Drug Might Make Tumor Cells More Sensitive to Therapy
8. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
9. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
10. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
11. New Research Shows Physical Therapy as Effective as Arthroscopic Knee Surgery

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... Dec. 1 Sleep Solutions®, Inc...or home testing and evaluation of sleep-disordered...assett, M.D., as its chief executive officer. Has...are, during its growth from a $250 million healthc...eader in total population health, and its subseque...
(Date:12/1/2009)....J., Dec. 1 Siemens Hearing Instr...ding global manufacturer of hearing instruments, a...nternational,s Sound Beginnings program. The allia..., As part of the renewed partnership, Siemens is e...ree hearing instruments to both children and young...
(Date:12/1/2009)..., China, Dec. 1 /PRNewswire-Asia-FirstCall/ -- Tia... a manufacturer and supplier of,modernized traditi...ina, today,announced that it has received approval...ion (SFDA) to produce Pediatric Fever and Cough Or...val number Z20093060) and Antibacterial,and Anti-i...
Breaking Medicine Technology:Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 2Sleep Solutions, Inc. Names Richard Hassett, M.D., New CEO 3Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 2Siemens Hearing Instruments Renews Quota Partnership to Give the Gift of Hearing to Children and Young Adults in Need 3Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 2Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products 3Pharmacist Injects Cure for Ailing Businesses 62172 1Pharmacist Injects Cure for Ailing Businesses 62172 2Kansas City Prepares for Largest Free Health Clinic 62169 1Kansas City Prepares for Largest Free Health Clinic 62169 2FDAs Woodcock Discusses Pain Management and Drug Safety in Nov 26 2009 Issue of The New England Journal of Medicine 62164 1
... track to have Phase 3 data available by the sprin...zation applications expected by the .... 28 Human Genome,Sciences, Inc. (Nasdaq: HGSI )...and initial dosing ahead of schedule in ACHIEVE 1,...ron(R) (albinterferon alfa-2b) in,combination with...
...IND Meeting Scheduled For August 29, 2007, STOCKH...al AB (http://www.omxgroup.com, ticker: DIAM B; ...l announced today that NP2, the company,s first dr...system (NTDDS) gene therapy,platform, will be the ...eting with the U.S. Food and Drug Administration o...
Other Medicine Technology:Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 2Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 3Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 4Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule 5Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 2Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 3Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 4Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain 5
(Date:12/1/2009)... , , SAN DIEGO, Dec. 1 /PRNewswire-Fi...ied supplier of Farming, Nursery and Wellness prod...ing agreement with Southern California Micro-Lendi...m ). ,, Yan Skwara, CEO of US Farms, Inc. stat... partnership with Angels in Action utilizing our A...
(Date:12/1/2009)... , , BRUSSELS, December 1 /PRNewswir...perts Agree That Adapting Food,Production and Mode...ons , Prof. John Beddington, Chief Scient...ll agricultural policy must be founded on science ...cientific advisor with the,responsibility to look ...
(Date:12/1/2009)... Some become so worried about what might happen t..., , TUESDAY, Dec. 1 (HealthDay News) -- ...into depression, a new study suggests. , "Anxie...udy author Andres Viana, a graduate student in psy...ose with anxiety sensitivity are afraid of their a...
(Date:12/1/2009)... Radiation exposures in younger women may up chan... Dec. 1 (HealthDay News) -- Mammograms may actuall...k women, a new study suggests. , Dutch research...r examining the effect of low-dose radiation expos...mutation boosting breast cancer risk and two looki...
(Date:12/1/2009)... , Research released in the December 2009 issue o...ermine whether the survival improvement among pati... the last two decades as reported in controlled cl...sis of over 100,000 patients with stage IV non-sma... SEER database to evaluate trends in survival betw...
Breaking Medicine News(10 mins):Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 2Health News:US Farms, Inc. Announces Marketing Agreement With Micro Lending Institution Angels In Action 3Health News:Food Security to be the Top Issue for EU's Science Chief 2Health News:Fear of Anxiety May Lead to Depression 2Health News:Mammograms May Boost Cancer Risk in High-Risk Women 2
... increase your chance of having colorectal cancer/... Cancer Institute. Colon and rectum together ...cancer is also called colorectal cancer. Cancer of...tive Investigation into Cancer and Nutrition have ...
...patients with the help of seroquel is effective//,... severe disabling mental illness. Some of the symp...seen or heard, feelings of being persecuted, becom...ough most schizophrenic patients are not aggressiv...
... why the diabetes drug thiazolidinediones (TZDs) c...ity of Utah had found that the drug TZDs activates...or-activated receptor gamma (PPAR). This is situat...nerally used to lower blood sugar levels and lipid...
...tions of the gum may increase the risk of the Alzh...rly in life. According to a research study th...on International Conference on Prevention of Demen...nd slowly destroys them. The main symptoms of the ...
...p that can keep people have a long life//. An...he benefits of having friends do affect the health...t life expectancy can get significantly increased.... 70 years and above. Researchers had monitored fac...
...ranelate to be used for treating patients with ost...escribing the drug it is important to observe the ...in the British Medical Journal has said that the d...recent studies on the drug had shown the drug to b...
Other Medicine News:
...nd ULTIMA PLUS are the "ultimate finishing systems...se new products expand the finishing room proficie...ures at a very reasonable price. The ULTIMA Series...creen, Topcons precision 3D frame tracing, safety ...
Topcon FR-2 Frame Reader
...it color mapping software system enhances clinical...ull color corneal maps. The system offers an enlar...s, refractive and keratometric data, and periphera...tion of subclinical keratoconus as well as pre and...
TOPCON PD-5 Pupilometer
Medicine Products: